Neurotrope opens at record low after Alzheimer's drug fails trial

NextTrip

09/09/2019 14:35

** Drug developer's shares  NTRP.O  fall ~80% to 89 cents,
hitting record low
    ** Co says its treatment for Alzheimer's disease,
Bryostatin-1, failed a mid-stage trial  urn:newsml:reuters.com:*:nL3N2602WM
    ** Drug did not show any significant difference in patients
after 13 weeks versus placebo, co says
    ** It is the second time in more than two years the drug has
failed a trial
    ** NTRP to conduct full review of data to determine the path
forward
    ** Stock worst percentage loser across exchanges 
    ** Up to Friday's close, stock had risen 23.3% YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))